Nektar Therapeutics buy Maxi_Scalibusa
Start price
21.01.18
/
50%
€65.31
Target price
05.06.18
€193.48
Performance (%)
-25.52%
End price
05.06.18
€48.64
Summary
This prediction ended on 05.06.18 with a price of €48.64. The price of Nektar Therapeutics has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -25.52%. Maxi_Scalibusa has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Nektar Therapeutics | -4.788% | -4.788% | 134.268% | -89.378% |
| iShares Core DAX® | -0.268% | 5.471% | 14.271% | 19.027% |
| iShares Nasdaq 100 | 1.854% | 7.851% | 35.426% | 58.415% |
| iShares Nikkei 225® | 0.284% | 1.729% | 9.943% | 7.045% |
| iShares S&P 500 | 1.178% | 5.269% | 27.989% | 49.400% |
Comments by Maxi_Scalibusa for this prediction
In the thread Nektar Therapeutics diskutieren
(Vom Mitglied beendet)